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Abstract
Objective—To describe the administration of sedatives and analgesics at the end of life in a large 
cohort of infants in North American neonatal intensive care units (NICUs).
Study design—Data on mortality and sedative and analgesic administration were obtained from 
infants who died from 1997–2012 in 348 NICUs managed by the Pediatrix Medical Group. 
Sedatives and analgesics of interest included opioids (fentanyl, methadone, morphine), 
benzodiazepines (clonazepam, diazepam, lorazepam, midazolam), central alpha-2 agonists 
(clonidine, dexmedetomidine), ketamine, and pentobarbital. We used multivariable logistic 
regression to evaluate the association between administration of these drugs on the day of death 
and infant demographics and illness severity.
Results—We identified 19,726 infants who died. Of these, 6188 (31%) received a sedative or 
analgesic on the day of death; opioids were most frequently administered, 5366/19,726 (27%). 
Administration of opioids and benzodiazepines increased during the study period, from 16/283 
(6%) for both in 1997 to 523/1465 (36%) and 295/1465 (20%) in 2012, respectively. Increasing 
gestational age, increasing postnatal age, invasive procedure within 2 days of death, more recent 
year of death, mechanical ventilation, inotropic support, and antibiotics on the day of death were 
associated with exposure to sedatives or analgesics.
Conclusions—Administration of sedatives and analgesics increased over time. Infants of older 
gestational age and those more critically ill were more likely to receive these drugs on the day of 
death. These findings suggest that drug administration may be driven by severity of illness.
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End-of-life care for dying patients is central to the provision of quality health care.1 
Research efforts have sought to understand current management and identify best practices 
of end-of-life care.1 Although most of these efforts focus on critically ill adults, systematic 
data are urgently needed to guide end-of-life care for children and their families.1-4 Existing 
data suggest that high-quality end-of-life care for children includes interventions for relief of 
pain and other symptoms, most often by pharmacotherapy.2,3,5,6 Increasing recognition of 
pain in the neonatal period, historical evidence of limited administration of analgesia to 
infants undergoing painful procedures, and the high incidence of infant deaths compared to 
pediatric deaths outside this period offer unique opportunities to evaluate drug 
administration to infants at the end of life.7-9
Data on drug administration at the end of life in North American neonatal intensive care 
units (NICUs) are few.9-14 In a 4-center study (2 in the United States and 1 each in Canada 
and the Netherlands), providers most frequently administered opioids, 116/151 (77%), and 
benzodiazepines, 61/151 (41%), to dying infants.11 At each center, providers increased 
doses of opioids or benzodiazepines as the time of death approached; however, there was 
great variability among the centers in the doses given to achieve infant comfort.11 In 4 U.S. 
studies, providers also variably administered opioids or benzodiazepines during the process 
of ventilator withdrawal or withholding in infants.9,12-14 Variable drug administration may 
be due to patient- or provider-level characteristics.15-20 Here, we describe the administration 
of sedatives and analgesics at the end of life to a large cohort of infants in NICUs in North 




We identified all infants who died from 1997 to 2012 in 348 NICUs managed by the 
Pediatrix Medical Group. Data were obtained from the Pediatrix Medical Group Clinical 
Data Warehouse. The Pediatrix Clinical Data Warehouse prospectively captures data entered 
from history and physicals, daily notes, and discharge notes. These data include maternal 
history and demographics, administered drugs, laboratory results, culture results, and 
diagnoses. Drug dosing, intervals, and indications were not recorded.
Definitions
Sedatives and analgesics of interest included opioids (fentanyl, methadone, morphine), 
benzodiazepines (clonazepam, diazepam, lorazepam, midazolam), central alpha-2 agonists 
(clonidine, dexmedetomidine), ketamine, and pentobarbital. Infants were classified as 
exposed to a drug of interest if there was documentation of drug administration on the day of 
death or on either of the last 2 days of life. Infants who had a documented drug start date 
within 7 days of death but no documented end date were also presumed to be exposed to 
drugs of interest on the day of death. We evaluated infant severity of illness by exposure to 
antibiotics, inotropes, and mechanical ventilation on the day of death, and exposure to an 
invasive procedure within 2 days of death. We categorized NICUs based on average annual 
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discharges (low volume, <300 infants; medium volume, 301–600 infants; large volume, 
>600 infants).
Statistical Methods
We used standard summary statistics including counts, percentages, and medians with 
interquartile ranges to describe the study variables. We determined the number of infants 
exposed to sedatives and analgesics on the day of death, on either of the last 2 days of life, 
and at any time during their hospitalization. We compared the proportion of infants exposed 
to sedatives and analgesics on the day of death, on either of the last 2 days of life, and at any 
time during their hospitalization by gestational age, NICU volume, and year of death using 
chi-square tests of association. We performed univariable logistic regressions to evaluate the 
association between (1) sedative and analgesic exposure on the day of death, on either of the 
last 2 days of life, and at any time during their hospitalization, and (2) the following 
variables: gestational age, postnatal age, race/ethnicity, gender, invasive procedure within 2 
days of death, and inotrope, antibiotic, and ventilator exposure on the day of death. For 
multivariable modeling, we included all covariates that may be clinically associated with 
sedative and analgesic exposure on the day of death. The final model included random 
effects for NICU site and the following covariates: race/ethnicity, gestational age, postnatal 
age, invasive procedure within 2 days of death, year of death, and inotropic support, 
antibiotic exposure, and ventilator status on the day of death.
We performed a sensitivity analysis, limiting our cohort to infants admitted to the NICU for 
at least 2 days. STATA 12 (College Station, TX) was used to perform the statistical analysis. 
A P < .05 was considered statistically significant for all tests. The study was approved by 
the Duke University Institutional Review Board without the need for written informed 
consent as the data were collected without identifiers.
RESULTS
Demographics
We identified 19,726 infants who died during their NICU admission from 1997 to 2012. The 
median gestational age at birth, birth weight, and postnatal age on the day of death were 26 
weeks (interquartile range 24, 32), 820 g (615, 1641), and 8 days (2, 21), respectively. Of 
the 19,726 infants, 6188 (31%) received a sedative or analgesic on the day of death, 6601 
infants (33%) received a sedative or analgesic within the last 2 days of life, and 9538 (48%) 
received a sedative or analgesic at any point during their hospitalization. The median 
gestational age and birth weight were higher in infants who received sedatives and 
analgesics on the day of death compared to those who did not, 27 weeks (24, 33) vs. 26 
weeks (24, 32) (P < 0.001), and 861 g (633, 1790) vs. 800 g (605, 1570) (P < 0.001), 
respectively (Table I). Of the 19,726 infants, 5366 (27%) received an opioid on the day of 
death, and 3142 (16%) received a benzodiazepine on the day of death (Table II; online).
The use of sedatives or analgesics varied widely across centers and over time. The 
proportion of infants exposed to a sedative or analgesic on the day of death varied across 
NICUs (median 18%, interquartile range 0, 34) (Figure 1). Centers with the highest use 
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administered sedatives and analgesics to approximately 60% of dying infants. The overall 
use of opioids on the day of death increased during the study period, from 16/283 infants 
(6%) in 1997 to 523/1465 infants (36%) in 2012 (P < 0.001) (Figure 2). The overall use of 
benzodiazepines on the day of death also increased from 16/283 (6%) in 1997 to 295/1465 
(20%) in 2012 (P < .001).
On multivariable analysis, exposure to sedatives or analgesics on the day of death was 
associated with increasing gestational age, increasing postnatal age, invasive procedure 
within 2 days of death, more recent year of death, mechanical ventilation, inotropic support, 
and antibiotics on the day of death (Table III, Figure 3; online).
Sensitivity Analysis
We repeated our analysis limiting our cohort to infants admitted for at least 2 days. This 
included 16,197 (82%) infants from the original cohort of 19,726. Of the 16,197 infants, 
5504 (34%) received a sedative or analgesic on the day of death, 5917 (37%) received a 
sedative or analgesic within the last 2 days of life, and 8830 (55%) received a sedative or 
analgesic at any point during their hospitalization. Of the 1172 infants who died in 2012, 
527 (45%) received a sedative or analgesic on the day of death, 550 (47%) received a 
sedative or analgesic within the last 2 days of life, and 770 (66%) received a sedative or 
analgesic at any point during their hospitalization. The demographics of these infants were 
similar to the original cohort. Infants who received a sedative or analgesic were more likely 
to have died more recently, be of older gestational age, be on inotropic support, be receiving 
antibiotics, and to have undergone an invasive procedure in the 2 days prior to death.
DISCUSSION
We found that sedative and analgesic administration to dying infants is limited but increased 
over time. Limited administration of these drugs has also been shown in the setting of 
painful procedures, with only one-fifth of painful procedures in 430 infants performed with 
initiation of analgesic therapy.7 Limited sedative and analgesic use both prior to death and 
during painful procedures may be explained by numerous factors, including perception of 
physiology not conducive to experiencing pain (i.e., severe brain injury or comatose),15,21 
sudden and unexpected infant death or death in code situations, limited data regarding 
pharmacokinetics and safety of sedatives and analgesics in infant populations,22 few 
validated tools to assess pain and no tools to assess suffering in dying infants,23 health care 
team characteristics and interactions,24 and fear of litigation and hastening of death.11 In 
addition, data from 2 large randomized controlled trials suggested little improvement in 
analgesia and no change in the risk of poor neurologic outcome with continuous infusion of 
opioids during mechanical ventilation.25-27 These findings may have also contributed to the 
perception that infants should not be exposed to opioids, even in the setting of death.
Our results also demonstrate that, over the last 15 years, the proportion of infants who died 
and were exposed to sedatives or analgesics on the day of death increased over time. The 
increasing use over time may reflect increased public interest and knowledge about 
palliative care and potential deficiencies that exist;1,28 dissemination of evidence that 
premature infants have the anatomic, neurophysiological, and hormonal components 
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necessary to experience pain and that the experience of pain in the newborn period may be 
associated with significant short-term morbidity and poor long-term neurodevelopmental 
outcomes;29-35 and an increase over time in postnatal age at death.36 Similar to the 
association between older postnatal age and receipt of sedatives and analgesics, we also 
found that infants of older gestational age were more likely to be exposed to these drugs on 
the day of death. This finding is consistent with previous evidence that infants of lower birth 
weight (<800 g) were less likely to receive drugs for comfort at the end of life.13 Limited 
drug administration for younger and smaller infants may reflect larger societal values of 
infant personhood and be a consequence of limited methods for detecting discomfort and 
suffering in the most premature infants.37
In contrast to our results, a recent study of end-of-life care of 151 infants in 4 tertiary NICUs 
found that the majority (79–97%) of infants received drugs for comfort in the 48 hours 
before their deaths.11 Similarly, other studies of small cohorts of infants in North American 
and European NICUs have reported frequent administration of sedatives and analgesics 
during withdrawal of life support.9,16,17,38 Evidence also suggests that providers frequently 
administer sedatives and analgesics to dying children.10 In a study of 53 patients at 3 
teaching hospitals, 87% received sedatives and analgesics prior to death.21 Similarly, 
anticipation and treatment of symptoms during withdrawal of life support in adult patients is 
a near universally accepted phenomenon, with most controversy regarding what doses of 
sedatives and analgesics are medically, culturally, and legally acceptable in this setting.2,5,39 
In a study of 60 adult patients in a Dutch intensive care unit, 80% received opioids and 67% 
received sedatives during withdrawal of life support.40 Those who did not receive drugs 
were more likely to have acutely devastating neurologic disease.40
The differences between the results of available studies and our findings may be 
multifactorial. Previous work has suggested significant variation among neonatologists in 
end-of-life administration of analgesics and sedatives, and these variations differ by country 
or region, often resulting from the influence of culture and local law.11,19,41-45 Similarly, our 
results demonstrate significant variation in end-of-life use of sedatives and analgesics by 
site. Unlike our study, other studies on neonatal end-of-life sedative and analgesic 
administration involve ≤4 centers. The results of these smaller studies may represent the 
practice of individual providers.
Our study is limited by collection of medications entered into the daily progress note on the 
day of death. We acknowledge that we may miss medications administered at the bedside 
but not recorded in the medical record during the last stages of death or withdrawal of 
support. This limitation likely leads to underreporting of drug administration. However, in 
our study, drug administration was approximately 60% in some centers, which is similar to 
findings in smaller studies.36
Also among our limitations, the database used for this study also lacks dosing information 
that could reveal escalation of drug dosing in an attempt to provide comfort, does not 
provide method of drug administration (e.g., continuous infusion or intermittent bolus 
doses), and cannot characterize intent of the provider in drug administration. We were also 
not able to differentiate infants who died because of withdrawal or withholding of life-
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sustaining therapies from those who died suddenly or without a specific plan for the end of 
life.18 The distinction between death by decision and unexpected death would certainly 
influence outcomes and promote improved comparability between our study and others.18 
However, we assume that the distribution of mode of death in our cohort is similar to that in 
other studies. In prior studies, withdrawal or withholding of life support accounts for deaths 
in up to 73% of infants in tertiary NICUs, and death due to physiologic instability or 
requiring cardiopulmonary resuscitation outside of the delivery room occurs in less than 
10% of deaths in NICUs.14,18,46
Strengths of our study include the characterization of sedative and analgesic use at the end 
of life in the largest cohort of infants to date, characterization of sedative and analgesic 
administration in the general care of dying patients and not solely in the setting of 
withdrawal of life support, and determination of differences in center practice regarding 
sedative and analgesic management.
Opportunities exist to optimize end-of-life care for infants. Optimized care may be 
accomplished through the development of standardized protocols or formalized palliative 
care teams specific to the end-of-life needs in infants. However, more information is needed 
to identify the optimal components of such protocols and teams, and to develop a standard 
of care for infants at the end of life. Pertinent information may include the following: (1) 
reasons for limited sedative and analgesic administration to our most vulnerable pediatric 
patients; (2) methods to determine suffering in all infants, including at the end of life, and in 
extremely premature infants, those with hypoxic encephalopathy, and those with congenital 
anomalies; (3) reasons for variation in end-of-life sedative and analgesic administration 
among NICUs, including region of the United States, composition of medical providers, and 
state and local laws; (4) changes in drug dosing surrounding death; and (5) physician intent 
in drug administration at the end of life.
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Use of opioids (A) and benzodiazepines (B) on day of death among all sites with >10 deaths.
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Exposure to opioids and benzodiazepines by year of death (exposure on the day of death).
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Exposure to opioids and benzodiazepines on the day of death by (A) gestational age (weeks) 
at birth, (B) average annual center volume, and (C) postnatal age (days) at time of death.
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on day of death
(N = 13,538)
Sedative or analgesic








 <28 7868 (58) 3391 (55) 5488 (58)
 28-33 2661 (20) 1319 (21) 2044 (21)
 >33 2988 (22) 1469 (24) 2354 (25)
Male 7562 (56) 3558 (57) 5443 (57)
Birth weight (g)
 <750 5863 (43) 2402 (39) 3965 (42)
 750-999 2140 (16) 1014 (17) 1608 (17)
 1000-1499 1655 (12) 812 (14) 1180 (12)
 ≥1500 3786 (28) 1947 (31) 2768 (29)
Postnatal age (days)
 1 2551 (19) 565 (9) 1558 (16)
 2-7 5051 (37) 2719 (44) 2410 (25)
 8-28 3740 (28) 1877 (30) 3181 (33)
 >28 2092 (15) 1027 (17) 2365 25)
Postmenstrual age
 <28 5960 (44) 2476 (38) 3530 (37)
 28-33 3507 (26) 1748 (29) 2752 (29)
 ≥33 3946 (29) 1955 (33) 3221 (34)
Race/ethnicity
 White 5753 (42) 2684 (40) 4116 (43)
 Black 3237 (24) 1391 (22) 2239 (23)
 Hispanic 3225 (24) 1588 (26) 2349 (25)
 Other 674 (5) 317 (5) 486 (5)
Antibiotic support
a 4612 (34) 2881 (47)
Inotropic support
a 3703 (27) 2605 (42)
Procedure
b 266 (2) 320 (5)
Ventilation support
a 11,492 (85) 5800 (94)
Values are expressed as n (%).
a
On the day of death.
b
Within 2 days of death.
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Table II

















Values are expressed as n (%).
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Table III
Predictors of sedative and analgesic exposure on the day of death
OR (95% CI)
Antibiotics on the day of death 1.75 (1.63, 1.89)
Gestational age (weeks)
<28 Reference
28-33 1.32 (1.21, 1.44)
>33 1.51 (1.38, 1.68)
Year of death 1.15 (1.13, 1.16)
Inotropic support 1.65 (1.53, 1.77)
Invasive procedure within 2 days of death 1.98 (1.63, 2.39)
Mechanical ventilation 2.06 (1.82, 2.34)
Postnatal age (days)
<3 Reference
≥3 1.64 (1.53, 1.77)
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